結合疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、疾病適應症、最終用戶、地區和競爭格局分類，2021-2031年

全球結合疫苗市場預計將從 2025 年的 196.9 億美元成長到 2031 年的 340.5 億美元，複合年成長率為 9.56%。

這些疫苗是透過將弱抗原（通常是細菌多醣）共用價結合到載體蛋白上而製成的，這一過程能夠引發強烈的免疫反應。這種化學結合將T細胞非依賴性抗原轉化為T細胞依賴性抗原，從而有效誘導免疫記憶並確保疫苗對嬰幼兒的有效性。該領域的發展主要得益於肺炎球菌和腦膜炎球菌病菌感染在全球範圍內的日益蔓延、這些生物製藥被頻繁納入國家免疫規劃，以及國際組織對開發中國家疫苗接種活動的大量資金支持。

儘管存在這些市場促進因素，但市場仍面臨許多障礙，例如高昂的製造成本和複雜的生產流程，導致資源匱乏地區難以獲得這些產品。這些複雜的生產要求造成供應瓶頸和價格上漲，阻礙了全民普及。例如，世界衛生組織（世衛組織）在2025年報告稱，到2024年底，肺炎球菌結合疫苗將在163個成員國投入使用，實現全球67%的三劑接種覆蓋率。這項數據既凸顯了這些生物製藥的廣泛可及性，也反映了全球免疫覆蓋率仍然存在的差距。

市場促進因素

世界衛生組織加強疫苗供應的策略性舉措正在從根本上改變市場格局。這些組織正與各國政府合作，將結合疫苗納入國家規劃，尤其是在非洲腦膜炎帶等高負擔地區。透過保障供應鏈和補貼採購成本，這些措施確保了拯救生命的疫苗能夠惠及先前缺乏足夠服務的弱勢族群。一個顯著的例子是，一種新型五價腦膜炎雙球菌結合疫苗被納入一個非洲主要國家的公共衛生策略。根據全球疫苗免疫聯盟（Gavi）2024年4月發布的關於奈及利亞Men5CV疫苗上市的新聞稿，該聯盟透過支持一項旨在控制疫情、覆蓋一百萬人的緊急宣傳活動，展現了這些協調努力的規模。

同時，強大的臨床開發平臺和新型多價疫苗的上市正在推動市場成長並擴大保護範圍。製造商正將重點從兒童特定適應症轉向全面的成人策略，開發覆蓋更廣泛血清型的製劑以降低抗生素抗藥性。這項創新旨在提供對不斷演變的細菌菌株的更廣泛保護，並為醫護人員提供更強大的侵襲性疾病預防工具。作為這項進展的象徵，默克公司於2024年6月宣布，首款專為成人設計的21價肺炎鏈球菌結合疫苗CAPVAXIVE已獲得FDA核准。這些商業性里程碑直接轉化為巨大的經濟價值。例如，輝瑞公司報告稱，光是2024年第三季度，其Prevner產品系列的全球銷售額就達到了18億美元。

市場挑戰

阻礙全球結合疫苗市場成長的主要障礙是其生產流程相關的高昂成本和技術複雜性。這些生物製藥的生產需要複雜的化學偶聯工藝，將細菌多醣與蛋白質載體連接起來，這需要高度專業的設施和先進的技術。這些嚴格的生產標準要求對基礎設施和品管系統進行大量資本投資，從而為新生產商設置了很高的進入門檻。因此，市場仍然集中在大型製藥企業手中，限制了競爭，並推高了價格，從而限制了對成本敏感的市場中的採購。

這種生產能力的集中導致供應鏈脆弱性和獲取不均，尤其是在當地生產能力低度開發的發展中地區。由於無法在本地生產複雜的配方，不得不依賴昂貴的進口產品，這往往導致供不應求和市場滲透延遲。例如，全球疫苗免疫聯盟（Gavi）在2024年發布的報告顯示，非洲大陸的疫苗產量僅佔全球供應量的約0.1%，這意味著該地區幾乎完全依賴進口疫苗。缺乏分散的生產能力阻礙了高效拓展市場至高需求且資源有限的地區的潛力。

市場趨勢

合成結合疫苗生產技術的進步正在從根本上改變疫苗生產模式，超越了傳統的化學偶聯方法。這一趨勢的特點是採用無細胞蛋白合成和特異性偶聯技術，克服了傳統生產過程的技術限制。與添加多種血清型時面臨載體抑制和空間位阻等問題的標準製程不同，合成平台能夠在不影響免疫抗原性的前提下，精確組裝高價值的多血清型製劑。大量資金湧入採用這些技術的公司，充分證明了這項技術轉變的商業性可行性。例如，2024年9月，Vaxcyte宣布透過首次股票公開發行資金籌措億美元，用於推進其旨在提供更廣泛保護的合成疫苗研發管線。

同時，非傳染性疾病治療性結合疫苗的出現表明，市場關注正從傳統感染疾病轉向其他領域。研究人員和新興企業正在加速將結合技術應用於物質使用疾患的治療，他們開發出的製劑中，Fentanyl和海洛因衍生物等藥物半抗原與免疫抗原性載體蛋白結合。這些疫苗透過誘導產生抗體來中和藥物的精神活性作用，這些抗體能夠捕獲血液中的目標藥物，從而阻止藥物穿過血腦障壁。這項應用正在將目標市場拓展到成癮治療領域，並吸引新的投資。根據《達拉斯晨報》2024年9月報道，生物製藥Start-UpsObax截至2024年6月已籌集超過1000萬美元，用於推進一種新型Fentanyl結合疫苗的人體資金籌措試驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球結合疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（單價合併疫苗、多價合併疫苗）
  • 特定疾病（肺炎鏈球菌、流感、腦膜炎雙球菌、傷寒）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美結合疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲結合疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區結合疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲結合疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲結合疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球結合疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Sanofi SA
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Conjugate Vaccine Market is projected to expand from USD 19.69 Billion in 2025 to USD 34.05 Billion by 2031, reflecting a compound annual growth rate of 9.56%. These vaccines are created by covalently bonding a weak antigen, typically a bacterial polysaccharide, to a carrier protein, a process that triggers a robust immune response. This chemical linkage transforms T-cell independent antigens into T-cell dependent ones, effectively inducing immunological memory and ensuring potency in infants. Growth in this sector is largely fueled by the increasing global prevalence of pneumococcal and meningococcal diseases, alongside the frequent inclusion of these biologics in national immunization protocols and substantial financial support from international bodies for vaccination efforts in developing countries.

Despite these drivers, the market encounters significant obstacles due to the high costs and intricate nature of manufacturing, which limits availability in resource-constrained regions. These complex production demands frequently result in supply bottlenecks and elevated prices that hinder universal access. To illustrate the current scale of deployment, the World Health Organization reported in 2025 that the pneumococcal conjugate vaccine had been introduced in 163 Member States by late 2024, achieving a global third-dose coverage of 67%. This statistic underscores both the widespread distribution of these biologics and the persistent gaps remaining in global immunization coverage.

Market Driver

Strategic initiatives by global health organizations to enhance vaccine availability are fundamentally reshaping the market landscape. These entities collaborate with governments to introduce conjugate vaccines into national programs, particularly in high-burden areas such as the African meningitis belt. By securing supply chains and subsidizing procurement costs, these initiatives ensure that life-saving formulations reach vulnerable populations that were previously underserved. A prime example of this expansion occurred when a major African nation integrated a novel pentavalent meningococcal conjugate vaccine into its public health strategy. According to Gavi, the Vaccine Alliance, in an April 2024 press release regarding Nigeria's introduction of the Men5CV vaccine, the alliance supported an emergency campaign targeting 1 million people to halt an outbreak, demonstrating the scale of these coordinated efforts.

Concurrently, a strong clinical pipeline and the launch of novel multivalent vaccines are driving market growth and broadening the scope of protection. Manufacturers are increasingly shifting focus from pediatric-only indications to comprehensive adult strategies, developing formulations that cover a wider array of serotypes to mitigate antimicrobial resistance. This innovation aims to provide broader coverage against evolving bacterial strains, offering healthcare providers more potent tools to prevent invasive disease. Highlighting this advancement, Merck & Co., Inc. announced in June 2024 that the FDA approved CAPVAXIVE, the first 21-valent pneumococcal conjugate vaccine specifically designed for adults. Such commercial milestones translate into significant financial value; for instance, Pfizer Inc. reported that its Prevnar franchise generated $1.8 billion in global revenues during the third quarter of 2024 alone.

Market Challenge

The primary obstacle hampering the growth of the Global Conjugate Vaccine Market is the substantial cost and technical complexity associated with the manufacturing process. Producing these biologics requires intricate chemical conjugation procedures to link bacterial polysaccharides with protein carriers, a step that demands highly specialized facilities and advanced technical expertise. These rigorous production standards necessitate significant capital investment in infrastructure and quality control systems, creating high barriers to entry for new manufacturers. Consequently, the market remains concentrated among a limited number of major pharmaceutical players, which restricts competition and keeps unit prices elevated, thereby limiting procurement volumes in cost-sensitive markets.

This concentration of manufacturing capacity results in supply chain vulnerabilities and unequal access, particularly in developing regions where local production capabilities are absent. The inability to manufacture these complex formulations locally forces reliance on expensive imports, which often leads to supply shortages and slower market penetration. Illustrating this disparity, Gavi, the Vaccine Alliance reported in 2024 that the African continent produced only approximately 0.1% of the global vaccine supply, leaving the region almost entirely dependent on imported doses. This lack of distributed manufacturing capability hampers the market's potential to expand efficiently into high-demand, resource-constrained geographies.

Market Trends

Advancements in synthetic conjugate vaccine manufacturing are fundamentally altering production paradigms by moving beyond traditional chemical conjugation methods. This trend is characterized by the adoption of cell-free protein synthesis and site-specific linkage technologies, which circumvent the technical limitations of conventional manufacturing. Unlike standard processes that struggle with carrier suppression and steric hindrance when adding multiple serotypes, synthetic platforms enable the precise assembly of high-valency formulations without compromising immunogenicity. The commercial viability of this technological shift is evident in the substantial capital flowing into companies pioneering these methods; for example, Vaxcyte, Inc. announced in September 2024 that it raised significant funds through a $1.3 billion public offering to advance its synthetic vaccine pipeline aimed at producing broader-spectrum protection.

Simultaneously, the emergence of therapeutic conjugate vaccines for non-communicable diseases represents a divergence from the market's traditional infectious disease focus. Researchers and startups are increasingly leveraging conjugate technology to treat substance use disorders by engineering formulations where drug haptens, such as fentanyl or heroin derivatives, are coupled to immunogenic carrier proteins. These vaccines induce the production of antibodies that sequester the target drug in the bloodstream, preventing it from crossing the blood-brain barrier and thereby neutralizing its psychoactive effects. This application expands the addressable market into addiction medicine, attracting new streams of investment. As reported by The Dallas Morning News in September 2024, the biopharmaceutical startup Ovax had raised over $10 million by June 2024 to progress a novel fentanyl conjugate vaccine into human clinical trials.

Key Market Players

• Sanofi S.A
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

Report Scope

In this report, the Global Conjugate Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Conjugate Vaccine Market, By Product Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccine

Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• Meningococcal
• Typhoid

Conjugate Vaccine Market, By End-User

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Conjugate Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Conjugate Vaccine Market.

Available Customizations:

Global Conjugate Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Conjugate Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
  • 5.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Conjugate Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Conjugate Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Conjugate Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Conjugate Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End-User

7. Europe Conjugate Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Conjugate Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Conjugate Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Conjugate Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Conjugate Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Conjugate Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By End-User

8. Asia Pacific Conjugate Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Conjugate Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Conjugate Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Conjugate Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Conjugate Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Conjugate Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Conjugate Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Conjugate Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Conjugate Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Conjugate Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End-User

10. South America Conjugate Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Disease Indication
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Conjugate Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Conjugate Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Conjugate Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Conjugate Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Merck & Co. Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. Bharat Biotech International Limited
• 15.6. Serum Institute of India Pvt. Ltd
• 15.7. Biological E. Limited
• 15.8. Bavarian Nordic A/S
• 15.9. CSL Limited
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer